SAJAL KUMAR JHA

Dr. SAJAL KUMAR JHA

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2014 in International Scholarly Research Notices
Verified
Journal Article
Open access
PDF file
SJSAJAL KUMAR JHA
SAJAL KUMAR JHA
RKRoopa Karki
Roopa Karki
VPVenkatesh Dinnekere Puttegowda
Venkatesh Dinnekere Puttegowda
DHD. Harinarayana
D. Harinarayana
The absolute bioavailability of famotidine after oral administration is about 40–45% and absorbance only in the initial part of small intestine may be due to low intestinal permeability. Hence, an olive oil based microemulsion formulation with Tween-80 as surfactant and PEG-400 as cosurfactant was developed by using water titration method with the aim of enhancing the intestinal permeability as well as oral bioavailability. In vitro drug permeation in intestine after 8 h for all formulations varied from 30.42% to 78.39% and most of the formulations showed enhanced permeation compared to pure drug (48.92%). Famotidine microemulsion exhibited the higher absorption and Cmax⁡ achieved from the optimized famotidine formulation (456.20 ng·h/ml) was higher than the standard (126.80 ng·h/mL). It was found that AUC0–24 h obtained from the optimized famotidine test formulation (3023.5 ng·h/mL) was significantly higher than the standard famotidine (1663.3 ng·h/mL). F-1 demonstrated a longer (6 h) Tmax⁡ compared with standard drug (2 h) and sustained the release of drug over 24 h. The bioavailability of F-1 formulation was about 1.8-fold higher than that of standard drug. This enhanced bioavailability of famotidine loaded in microemulsion system might be due to increased intestinal permeability.

29 December 2025 in Journal of Pharmaceutical Innovation
Verified
Journal Article
Closed access
PDF file
SMSubhabrota Majumdar
Subhabrota Majumdar
SCSailee Chowdhury
Sailee Chowdhury
PMPrasenjit Mondal
Prasenjit Mondal
SJSAJAL KUMAR JHA
SAJAL KUMAR JHA
RMRana Mazumder
Rana Mazumder

8 August 2025 in Biomedical Materials & Devices
Verified
Journal Article
Closed access
PDF file
KDKoustav Dutta
Koustav Dutta
BBBiswajit Basu
Biswajit Basu
RGRajdip Goswami
Rajdip Goswami
SGSourav Ghosh
Sourav Ghosh
MRMeghamouli Rana
Meghamouli Rana
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati

20 October 2014 in Advances in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SJSAJAL KUMAR JHA
SAJAL KUMAR JHA
RKRoopa Karki
Roopa Karki
VPVenkatesh Dinnekere Puttegowda
Venkatesh Dinnekere Puttegowda
AGAmitava Ghosh
Amitava Ghosh
Ranitidine microemulsion was investigated for its pharmacodynamic and pharmacokinetic evaluation to find out the suitability of microemulsion as a potential drug delivery system in the treatment of ulcer. The bioavailability of ranitidine after oral administration is about 50% and is absorbed via the small intestine; this may be due to low intestinal permeability. Hence the aim of present investigation was to maximize the therapeutic efficacy of ranitidine by developing microemulsion to increase the intestinal permeability as well as bioavailability. A ground nut oil based microemulsion formulation with Tween-80 as surfactant and PEG-400 as cosurfactant was developed for oral delivery of ranitidine and characterized for physicochemical parameters. In pharmacodynamic studies, significant () variation in parameters estimated was found between the treated and control groups. Ranitidine microemulsion exhibited higher absorption and Cmax (863.20ng·h/mL) than the standard (442.20ng/mL). It was found that AUC024hr obtained from the optimized ranitidine test formulation (5426.5ng·h/mL) was significantly higher than the standard ranitidine (3920.4ng·h/mL). The bioavailability of optimized formulation was about 1.4-fold higher than that of standard drug. This enhanced bioavailability of ranitidine microemulsion may be used as an effective and alternative drug delivery system for the antiulcer therapy.